Life Sciences Trade Groups Warn Congress: International Reference Pricing Proposals Included in Bills like H.R. 3 Undermine Hope for Patients and America’s Leadership in Biomedical Innovation
While the 2018 legislative year marked arguably the most successful year ever for CLSA in Sacramento and provided a number of major policy issues on which to focus our energy, the 2019 legislative year was “death by a thousand cuts,” requiring CLSA to spread its attention broadly across a host of issues outside of our traditional areas of focus.
CLSA organized a multi-state life sciences association letter to House and Senate Leadership, expressing our strong concerns with recent legislative proposals that threaten to undermine America’s global leadership in biomedical innovation by introducing international reference pricing or foreign price controls.
On Oct. 22, CLSA, in partnership with Allergan and Edwards Lifesciences, hosted facility tour and roundtable discussion with the nearly 40 personnel, including state legislators, legislative staff, the Orange County Medical Association, and other key stakeholders to educate policymakers and stakeholders on the value of life sciences innovation in Orange County.
On Oct 17, CLSA and Covington & Burling, LLP hosted Keith Flanagan, Director, and Maarika Kimbrell, Deputy Director, of FDA’s Office of New Drugs (OND) for a roundtable discussion on drug development.
Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.
With the impending January 1, 2020 effective date of the California Consumer Privacy Act (CCPA), the Legislature considered multiple bills this year that sought to clarify the law’s requirements and facilitate businesses’ compliance.
On Sept. 19, House Speaker Nancy Pelosi (D-San Francisco) unveiled legislation in the form of the Lower Drug Costs Now Act (H.R. 3), an unprecedented sweeping proposal that would transfer most domestic drug pricing decision-making to U.S. and European government bureaucrats, and eviscerate the free market model that has promoted innovation, cures and treatments for millions of patients.
On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator Tom Umberg (D-Santa Ana). We look forward to working with Senator Umberg and his team to advance policies that improve patient health and bring positive change for California patients and their families.
CLSA President & CEO Mike Guerra pens an op-ed in Morning Consult regarding the dangers of policymakers utilizing foreign price controls to lower drug costs. With growing bipartisan support for these schemes, CLSA is working to educate policymakers that importing price controls will do little to lessen the financial burden for patients. Rather, these short-sighted proposals will hinder access to needed treatments and discourage medical innovation in California.